[go: up one dir, main page]

MA55694A - Méthodes de conditionnement de patients pour la thérapie cellulaire t - Google Patents

Méthodes de conditionnement de patients pour la thérapie cellulaire t

Info

Publication number
MA55694A
MA55694A MA055694A MA55694A MA55694A MA 55694 A MA55694 A MA 55694A MA 055694 A MA055694 A MA 055694A MA 55694 A MA55694 A MA 55694A MA 55694 A MA55694 A MA 55694A
Authority
MA
Morocco
Prior art keywords
methods
cell therapy
conditioning patients
conditioning
patients
Prior art date
Application number
MA055694A
Other languages
English (en)
Inventor
Adrian Bot
William GO
Rajul JAIN
James N Kochenderfer
Steven A Rosenberg
Jeffrey S Wiezorek
Original Assignee
Kite Pharma Inc
The Government Of The Us Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc, The Government Of The Us Secretary Department Of Health And Human Services filed Critical Kite Pharma Inc
Publication of MA55694A publication Critical patent/MA55694A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA055694A 2015-05-28 2016-05-27 Méthodes de conditionnement de patients pour la thérapie cellulaire t MA55694A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562167750P 2015-05-28 2015-05-28
US201562262143P 2015-12-02 2015-12-02

Publications (1)

Publication Number Publication Date
MA55694A true MA55694A (fr) 2022-02-23

Family

ID=57393284

Family Applications (2)

Application Number Title Priority Date Filing Date
MA043343A MA43343A (fr) 2015-05-28 2016-05-27 Méthodes de conditionnement de patients pour la thérapie cellulaire t
MA055694A MA55694A (fr) 2015-05-28 2016-05-27 Méthodes de conditionnement de patients pour la thérapie cellulaire t

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA043343A MA43343A (fr) 2015-05-28 2016-05-27 Méthodes de conditionnement de patients pour la thérapie cellulaire t

Country Status (19)

Country Link
US (4) US9855298B2 (fr)
EP (2) EP3302508A4 (fr)
JP (4) JP7197979B2 (fr)
KR (5) KR102349677B1 (fr)
CN (2) CN107921066A (fr)
AU (3) AU2016268864B2 (fr)
BR (1) BR112017025166A2 (fr)
CA (1) CA2986798A1 (fr)
CL (1) CL2017003006A1 (fr)
DO (1) DOP2017000271A (fr)
EA (1) EA201792649A1 (fr)
HK (2) HK1248141A1 (fr)
IL (7) IL318826A (fr)
MA (2) MA43343A (fr)
MX (4) MX2017015186A (fr)
PH (1) PH12017502154A1 (fr)
SG (2) SG10201913604TA (fr)
TW (4) TW202517279A (fr)
WO (1) WO2016191756A1 (fr)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
RU2636503C2 (ru) 2011-09-08 2017-11-23 Иеда Рисеч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN117427091A (zh) 2014-10-20 2024-01-23 朱诺治疗学股份有限公司 用于过继细胞治疗中的给药的组合物和方法
KR102481922B1 (ko) * 2015-05-28 2022-12-28 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
US9855298B2 (en) 2015-05-28 2018-01-02 Kite Pharma, Inc. Methods of conditioning patients for T cell therapy
PL3322424T3 (pl) 2015-07-16 2024-03-04 Yeda Research And Development Co., Ltd. Zastosowanie centralnych limfocytów t pamięci przeciwko stronie trzeciej
WO2017075451A1 (fr) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de pou2af1
WO2017075465A1 (fr) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de gata3
PE20190173A1 (es) 2016-04-01 2019-02-01 Kite Pharma Inc Receptores de antigenos quimericos y celulas t y metodos de uso
SMT202100564T1 (it) 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
CA3019835A1 (fr) 2016-04-08 2017-10-12 Purdue Research Foundation Methodes et compositions pour therapie par lymphocytes t car
WO2017180587A2 (fr) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Systèmes de biocircuits régulés
CN109477830A (zh) 2016-05-25 2019-03-15 昆士兰医学研究所理事会 免疫疗法的方法
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
EP3567049A4 (fr) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
CN110392736A (zh) * 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
BR112019014406A2 (pt) * 2017-01-20 2020-04-28 Atara Biotherapeutics Inc métodos de tratar esclerose múltipla usando células t autólogas
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
KR20200010179A (ko) 2017-02-27 2020-01-30 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법에 있어서 투약과 관련된 조성물, 제조 물품 및 방법
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US20180280437A1 (en) 2017-03-13 2018-10-04 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
SG11201907744QA (en) * 2017-04-01 2019-09-27 Avm Biotechnology Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
SG11201908980PA (en) 2017-04-03 2019-10-30 Kite Pharma Inc Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
WO2018191553A1 (fr) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Signature tumorale pour métastase, compositions de matière et leurs procédés d'utilisation
KR20190142775A (ko) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
WO2018209324A2 (fr) 2017-05-11 2018-11-15 The Broad Institute, Inc. Procédés et compositions d'utilisation de sous-types de lymphocytes infiltrant les tumeurs cd8 + et leurs signatures géniques
KR102426447B1 (ko) 2017-05-26 2022-07-29 카이트 파마 인코포레이티드 배아 중간엽 전구 세포를 제조하고 사용하는 방법
WO2018223101A1 (fr) * 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles de fabrication et procédés de traitement utilisant une thérapie cellulaire adoptive
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019014581A1 (fr) 2017-07-14 2019-01-17 The Broad Institute, Inc. Procédés et compositions pour moduler l'activité d'un lymphocyte cytotoxique
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
CN109593711A (zh) * 2017-10-02 2019-04-09 盖米达细胞有限公司 扩增自然杀手细胞部份的扩增方法及用途
WO2019084055A1 (fr) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology Classification de variation génétique à partir de transcriptomes unicellulaires
ES2989180T3 (es) 2017-10-31 2024-11-25 Allogene Therapeutics Inc Métodos y composiciones para la dosificación de células T con receptores de antígenos quiméricos alogénicos para tratar el linfoma de células B grandes refractario y/o recidivante o el linfoma folicular refractario y/o recidivante
BR112020008340A2 (pt) 2017-11-01 2020-11-17 Juno Therapeutics Inc processo para gerar composições terapêuticas de células modificadas
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11661611B2 (en) 2017-11-09 2023-05-30 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
EP3710039A4 (fr) 2017-11-13 2021-08-04 The Broad Institute, Inc. Méthodes et compositions de traitement du cancer par ciblage de la voie clec2d-klrb1
WO2019098682A1 (fr) 2017-11-14 2019-05-23 앱클론(주) Anticorps anti-her2 ou fragment de liaison à l'antigène de celui-ci, et récepteur antigénique chimérique le comprenant
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2019099707A1 (fr) 2017-11-16 2019-05-23 Kite Pharma, Inc Récepteurs antigéniques chimériques modifiés et procédés d'utilisation
US12161670B2 (en) 2017-12-08 2024-12-10 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
SG11202006416TA (en) 2018-01-15 2020-08-28 Pfizer Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
BR112020014913A2 (pt) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
BR112020015884A2 (pt) 2018-02-06 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
EP3755366A4 (fr) 2018-02-23 2021-12-29 Endocyte, Inc. Procédé de séquençage pour thérapie par lymphocytes t à car
KR20210013013A (ko) * 2018-03-09 2021-02-03 카르스젠 테라퓨틱스 리미티드 종양 치료 방법 및 조성물
EP3765094A4 (fr) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. Compositions de régulation génique et procédés pour améliorer l'immunothérapie
WO2019183455A1 (fr) 2018-03-22 2019-09-26 Windmil Therapeutics, Inc. Lymphocytes infiltrant la moelle osseuse spécifiques au cancer de la prostate et utilisations associées
WO2019191752A1 (fr) * 2018-03-30 2019-10-03 Ohio State Innovation Foundation Procédés de pré-conditionnement de patients pour la thérapie à lymphocytes t
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
JP7584299B2 (ja) 2018-05-23 2024-11-15 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現
WO2019232542A2 (fr) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Procédés et compositions pour détecter et moduler des signatures géniques micro-environnementales à partir du lcr de patients présentant des métastases
KR102734592B1 (ko) 2018-06-01 2024-11-27 카이트 파마 인코포레이티드 키메라 항원 수용체 t 세포 요법
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
EP3810780A1 (fr) 2018-06-22 2021-04-28 Kite Pharma Eu B.V. Compositions et procédés pour produire des lymphocytes t modifiés
CA3107383A1 (fr) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Utilisation d'un conjugue anticorps anti-cd5 -medicament (adc) dans une therapie cellulaire allogenique
CA3107378A1 (fr) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Utilisation d'un conjugue medicament anticorps anti-cd2 (adc) dans une therapie cellulaire allogenique
BR112021004383A2 (pt) 2018-09-28 2021-08-03 Massachusetts Institute Of Technology proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3632446B3 (fr) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Thérapies immunoablatives
EP3488851A1 (fr) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Thérapies immunoablatives
WO2020081730A2 (fr) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Méthodes et compositions pour moduler un microenvironnement
WO2020092848A2 (fr) * 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
CN113490504A (zh) * 2019-01-07 2021-10-08 美真达治疗公司 抗-cd45抗体药物缀合物(adc)在细胞疗法中的用途
CN118546960A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (fr) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions et méthodes de modulation de régulateurs métaboliques de pathogénicité de lymphocytes t
WO2020188573A1 (fr) * 2019-03-21 2020-09-24 Gamida-Cell Ltd. Fractions de cellules nk étendues appropriées pour une transplantation en polythérapie
US11090336B2 (en) 2019-03-27 2021-08-17 The Trustees Of The University Of Pennsylvania Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
PH12021500035A1 (en) 2019-04-12 2022-06-06 C4 Therapeutics Inc Tricyclic degraders of ikaros and aiolos
US20200384027A1 (en) 2019-05-03 2020-12-10 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
WO2020236967A1 (fr) 2019-05-20 2020-11-26 The Broad Institute, Inc. Mutant de délétion de crispr-cas aléatoire
WO2020243371A1 (fr) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Procédés et compositions pour la modulation de réponses immunitaires
AU2020301161B2 (en) 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
EP3990491A1 (fr) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Complexes protéine de fusion-hydroxyde métallique immunomodulateurs et leurs procédés
JP2022538836A (ja) 2019-06-27 2022-09-06 クリスパー セラピューティクス アクチェンゲゼルシャフト がんを治療するためのキメラ抗原受容体ｔ細胞及びｎｋ細胞阻害剤の使用
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021061648A1 (fr) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Méthodes et compositions pour la stimulation de réponses de lymphocytes t endogènes
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
IL292665B1 (en) * 2019-11-06 2025-10-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
US20230071910A1 (en) * 2020-01-24 2023-03-09 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
CA3172449A1 (fr) 2020-03-27 2021-09-30 Erik Hans MANTING Utilisation ex vivo de cellules modifiees d'origine leucemique pour ameliorer l'efficacite d'une therapie cellulaire adoptive
EP4125943A1 (fr) 2020-03-27 2023-02-08 Mendus B.V. Utilisation in vivo de cellules modifiées d'origine leucémique pour améliorer l'efficacité d'une thérapie cellulaire adoptive
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
WO2021260675A1 (fr) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents pour sensibiliser des tumeurs solides à un traitement
KR20230033647A (ko) 2020-06-30 2023-03-08 멘두스 비.브이. 난소암 백신에서 백혈병 유래 세포의 용도
WO2022093925A1 (fr) 2020-10-28 2022-05-05 Kite Pharma, Inc. Méthode de cytométrie de flux pour la caractérisation d'impuretés de lymphocytes t
JP2023547520A (ja) 2020-11-05 2023-11-10 メンドゥス・ベスローテン・フェンノートシャップ 免疫療法における腫瘍非依存性抗原の使用
EP4275044A1 (fr) 2021-01-10 2023-11-15 Kite Pharma, Inc. Thérapie par lymphocytes t
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
JP2024507199A (ja) 2021-02-20 2024-02-16 カイト ファーマ インコーポレイテッド 免疫療法を選択するための遺伝子マーカー
WO2022182891A1 (fr) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Récepteur antigénique chimérique ciblant ror1
KR20230173179A (ko) * 2021-05-14 2023-12-26 카이트 파마 인코포레이티드 키메라 항원 수용체 t세포 요법
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
EP4416292A2 (fr) 2021-10-14 2024-08-21 Arsenal Biosciences, Inc. Cellules immunitaires ayant des arnsh co-exprimés et des systèmes de porte logique
WO2023091954A2 (fr) 2021-11-19 2023-05-25 The Trustees Of The University Of Pennsylvania Antigène cd45 à spécificité pan-leucocytaire génétiquement modifié pour faciliter une thérapie de lymphocytes t car
US20230296610A1 (en) 2022-02-15 2023-09-21 Kite Pharma, Inc. Predicting adverse events from immunotherapy
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
WO2024092152A1 (fr) 2022-10-28 2024-05-02 Kite Pharma, Inc. Amélioration de l'efficacité et de la réponse durable de l'immunothérapie
EP4608987A1 (fr) 2022-10-28 2025-09-03 Kite Pharma, Inc. Facteurs d'optimisation de l'immunothérapie
CN120456925A (zh) * 2022-11-16 2025-08-08 恩卡尔塔公司 组合疗法的给药方案
DE102022132082B4 (de) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
DE102022132083B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132084B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
WO2024124044A1 (fr) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions et procédés ciblant sat1 pour améliorer l'immunité antitumorale pendant la progression d'une tumeur
CN120813368A (zh) 2023-03-03 2025-10-17 阿森纳生物科学公司 靶向psma和ca9的系统
AU2024241240A1 (en) 2023-03-17 2025-10-16 Kite Pharma, Inc. Impact of tumor microenvironment on efficacy of immunotherapy
WO2024211852A1 (fr) * 2023-04-07 2024-10-10 Fate Therapeutics, Inc. Cellule nk dérivée d'ipsc pour traitement de lymphome
WO2024243428A2 (fr) * 2023-05-24 2024-11-28 Instil Bio Inc. Utilisation de constructions de fusion pour thérapie cellulaire
WO2025006561A2 (fr) * 2023-06-27 2025-01-02 Nkarta, Inc. Méthodes de traitement utilisant des immunothérapies ciblant cd19
WO2025059533A1 (fr) 2023-09-13 2025-03-20 The Broad Institute, Inc. Enzymes crispr et systèmes
WO2025096419A1 (fr) 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. Lymphocytes t comprenant un récepteur antigénique chimérique ciblant le facteur de croissance transformant bêta et un récepteur de lymphocytes t ciblant un antigène tumoral, et leur utilisation
WO2025096517A1 (fr) 2023-11-01 2025-05-08 Kite Pharma, Inc. Facteurs pour optimiser l'efficacité d'une immunothérapie
WO2025097055A2 (fr) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions et méthodes d'utilisation de lymphocytes t en immunothérapie
WO2025117544A1 (fr) 2023-11-29 2025-06-05 The Broad Institute, Inc. Molécule de guidage oméga ingéniérisée et compositions iscb, systèmes et procédés d'utilisation associés
US20250290154A1 (en) 2024-03-04 2025-09-18 Kite Pharma, Inc. Predictive markers for immunotherapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030031652A1 (en) 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
AU2003265948B8 (en) * 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
CN107519499A (zh) 2010-03-23 2017-12-29 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG192010A1 (en) 2011-01-18 2013-08-30 Univ Pennsylvania Compositions and methods for treating cancer
EP2532740A1 (fr) 2011-06-11 2012-12-12 Michael Schmück Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
CN103946952A (zh) 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
CA3132353A1 (fr) 2012-05-08 2013-11-14 The Johns Hopkins University Methodes et compositions pour la perfusion de populations choisies de lymphocytes allogeniques a prise de greffe transitoire pour traiter le cancer
WO2014055657A1 (fr) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Utilisation d'une approche trans-signalisation dans des récepteurs d'antigènes chimériques
EP3010528B1 (fr) 2013-06-19 2019-09-11 Massachusetts Institute of Technology Ciblage in vivo de cellules avec des particules conjuguées à un ligand
BR112016010224A2 (pt) 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
IL254817B2 (en) * 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
KR102481922B1 (ko) * 2015-05-28 2022-12-28 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
US9855298B2 (en) 2015-05-28 2018-01-02 Kite Pharma, Inc. Methods of conditioning patients for T cell therapy
PE20190173A1 (es) * 2016-04-01 2019-02-01 Kite Pharma Inc Receptores de antigenos quimericos y celulas t y metodos de uso

Also Published As

Publication number Publication date
US9855298B2 (en) 2018-01-02
IL305621B2 (en) 2025-10-01
EP3302508A4 (fr) 2019-01-02
MX2023000051A (es) 2023-02-01
IL255887A (en) 2018-01-31
AU2022224754A1 (en) 2022-09-22
JP2025148404A (ja) 2025-10-07
IL255887B (en) 2022-09-01
EP3851110A1 (fr) 2021-07-21
TW202419092A (zh) 2024-05-16
IL305621B1 (en) 2025-06-01
CN107921066A (zh) 2018-04-17
US20170368101A1 (en) 2017-12-28
HK1246151A1 (zh) 2018-09-07
MX2023000049A (es) 2023-02-01
EP3302508A1 (fr) 2018-04-11
IL305621A (en) 2023-11-01
AU2025208570A1 (en) 2025-08-14
IL295224B2 (en) 2025-07-01
TW202517279A (zh) 2025-05-01
IL312426A (en) 2024-06-01
BR112017025166A2 (pt) 2018-07-31
JP7238030B2 (ja) 2023-03-13
IL318826A (en) 2025-04-01
US20180369283A1 (en) 2018-12-27
TWI868463B (zh) 2025-01-01
US20160346326A1 (en) 2016-12-01
IL284173A (en) 2021-07-29
MX2017015186A (es) 2018-07-06
PH12017502154A1 (en) 2018-05-28
KR20180011250A (ko) 2018-01-31
WO2016191756A1 (fr) 2016-12-01
DOP2017000271A (es) 2018-02-15
IL284173B1 (en) 2023-10-01
MX2023000050A (es) 2023-02-01
KR20250139881A (ko) 2025-09-23
TW202319057A (zh) 2023-05-16
CA2986798A1 (fr) 2016-12-01
HK1248141A1 (zh) 2018-10-12
KR102349677B1 (ko) 2022-01-12
IL295224B1 (en) 2025-03-01
JP2023071823A (ja) 2023-05-23
IL312426B1 (en) 2025-10-01
TW201717962A (zh) 2017-06-01
KR20230147769A (ko) 2023-10-23
KR20250136440A (ko) 2025-09-16
SG10201913613SA (en) 2020-03-30
US11491187B2 (en) 2022-11-08
JP7197979B2 (ja) 2022-12-28
AU2022224754B2 (en) 2025-08-28
IL295224A (en) 2022-10-01
US10322146B2 (en) 2019-06-18
KR20220008388A (ko) 2022-01-20
JP2021165291A (ja) 2021-10-14
TWI803447B (zh) 2023-06-01
MA43343A (fr) 2021-04-07
US12458654B2 (en) 2025-11-04
AU2016268864B2 (en) 2022-06-02
CL2017003006A1 (es) 2018-05-11
JP2018516915A (ja) 2018-06-28
IL316196A (en) 2024-12-01
US20230158075A1 (en) 2023-05-25
EA201792649A1 (ru) 2018-06-29
SG10201913604TA (en) 2020-02-27
CN114344321A (zh) 2022-04-15
AU2016268864A1 (en) 2017-12-07
IL284173B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MA55694A (fr) Méthodes de conditionnement de patients pour la thérapie cellulaire t
IL285965A (en) Ex vivo organ care system
IL284172A (en) Diagnostic methods for t cell therapy
EP3212233A4 (fr) Thérapie combinée pour le traitement d'une maladie
EP3263053A4 (fr) Instrument de traitement médical
IL253945B (en) kdm1a inhibitors to treat the disease
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
HUE059694T2 (hu) Készítmény rák kezelésére
EP3351189A4 (fr) Instrument de traitement pour endoscope
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
EP3266487A4 (fr) Instrument de traitement pour endoscope
EP3115012A4 (fr) Instrument de traitement pour endoscope
IL257355B (en) Selection of patients for combined treatment
IL256103B (en) Compositions and methods for treating celiac sprue disease
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
EP3318205A4 (fr) Instrument de traitement pour endoscope
EP3275380A4 (fr) Instrument de traitement pour endoscope
EP3269316A4 (fr) Instrument de traitement
EP3395270A4 (fr) Instrument de traitement endoscopique
AU2016272910B2 (en) Testing of a medical fluid treatment system
EP3329959A4 (fr) Instrument de traitement pour endoscope
EP3275495A4 (fr) Instrument de traitement
EP3323367A4 (fr) Instrument thérapeutique
EP3289994A4 (fr) Instrument de traitement
EP3222235A4 (fr) Instrument pour traitement chirurgical